阅读说明：本技术 一种混合细胞与仿真细胞培养人工巢装置中生产表皮生长因子的方法 (Method for producing epidermal growth factor in mixed cell and simulated cell culture artificial nest device ) 是由 华子昂 万君兴 竹添 孙宁 刘宝全 王娇 朱美瑛 张建 赵凯龙 于 2020-05-09 设计创作，主要内容包括：一种混合细胞与仿真细胞培养人工巢装置中生产表皮生长因子的方法,属于细胞因子类生物制品的智能制造领域。本发明生产表皮生长因子的步骤首先配制混合细胞培养液和细胞营养液,然后设置人工巢装置的参数并将混合细胞培养液装载到干细胞巢内,启动循环装置进行细胞培养,最后由收集到的细胞上清液使用ELISA试剂盒进行细胞因子检测。本发明利用对人工巢建立了人体内生产表皮生长因子时人体内的温度、营养、酸碱平衡、氧气平衡、二氧化碳平衡、代谢物排放模拟条件,使得表皮生长因子的合成较传统的2D细胞培养条件下更接近人体内的状况。(A method for producing epidermal growth factor in a mixed cell and simulated cell culture artificial nest device belongs to the field of intelligent manufacturing of cytokine biological products. The steps of the invention for producing the epidermal growth factor include firstly preparing mixed cell culture solution and cell nutrient solution, then setting parameters of the artificial nest device, loading the mixed cell culture solution into the stem cell nest, starting the circulating device for cell culture, and finally carrying out cytokine detection on collected cell supernatant by using an ELISA kit. The invention establishes simulation conditions of temperature, nutrition, acid-base balance, oxygen balance, carbon dioxide balance and metabolite emission in a human body when the epidermal growth factor is produced in the human body for the artificial nest, so that the synthesis of the epidermal growth factor is closer to the condition in the human body than the condition of the traditional 2D cell culture.)

1. A method for producing epidermal growth factor in a mixed cell and simulated cell culture artificial nest device is characterized by comprising the following steps:

s1, preparing a mixed cell culture solution and a cell nutrient solution;

s2, setting parameters of the artificial nest device;

s3, loading the mixed cell culture solution into the simulated artificial nest, and starting a circulating device to culture cells;

and S4, carrying out cytokine detection on the collected cell supernatant by using an ELISA kit.

2. The method of claim 1, wherein the mixed cell culture solution of step S1 comprises 60-80% by volume of human fibroblasts, 1% by volume of mast cells, macrophages, dendritic cells, Langerhans cells and chromophagous cells, 0.5% by volume of epidermal stem cells, 0.005% by volume of CD4+ T cells, 0.01% by volume of CD8+ T cells, and a cell density of 1 × 10%⁷mL, the remainder was supplemented with cell nutrient solution.

3. The method of claim 2, wherein the cell nutrient solution comprises the following components: 50ng/L of angiotensin, 98 mu g/L of aldosterol, 66pg/L of B-type natriuretic peptide, 2.26nmol/L of digoxin, 55 mu g/L of hyaluronic acid, 28 mu g/L of laminin, 56 mu g/L of IV-type collagen, 75 mu g/L of III-type procollagen peptide, 10.2nmol/L of folic acid, 396pmol/L of vitamin B12, 3mmol/L of glucose, 136mmol/L of sodium ion, 5mmol/L of potassium ion, 1mmol/L of magnesium ion and 2.2mmol/L of calcium ion.

4. The method of claim 3, wherein the cell nutrient solution further comprises Salvia miltiorrhiza 10ng/L and quercetin 5 ng/L.

5. The method of claim 1, wherein the parameters of the artificial nest device in step S2 are: the pressure is 90-220mmHg, the pH is 7.35-7.45, the temperature is 36.2-37.5 ℃, the oxygen content is 15-50 mL/100mL, and the carbon dioxide content is 30-80 mL/100 mL.

6. The method for producing EGF in mixed cell and mock cell culture artificial nest device according to claim 1, wherein the artificial nest device in step S3 is operated as follows:

s3.1, before the device operates, the spleen area (5) does not contain nutrient solution, a first control valve (8) of the liver area (3) is opened to enable the nutrient solution (26) to be actively conveyed from the stomach area (7) to the spleen area (5) and reach the lowest set value of the liquid level of the spleen area (5), under the driving of the power of the heart area (2), the nutrient solution reaches the heart area (2) and enters the lung area (4), and the nutrient solution receives oxygen and carbon dioxide from the gas permeable membrane (17) in the lung area (4) and then enters the artificial nest (1) to provide nutrition and oxygen for cells wrapped in the simulated extracellular matrix; the gas exchange is powered by the cooperation of a second peristaltic pump (9) and a second control valve (10), and the oxygen and the carbon dioxide are provided by sterile air (25);

s3.2, the nutrient solution flows out of the artificial nest (1) through a third control valve (11) and enters the spleen area (5);

s3.3, part of nutrient solution in the spleen area (5) and the nutrient solution (26) from the liver area (3) enter the heart area (2) together, pass through the lung area (4) and then enter the stem cell nest (1) to supply nutrition and oxygen for the stem cells; the other part is driven by a third peristaltic pump (12) to enter the renal area (6) and returns to the spleen area (5) through a fourth control valve (13); the dialysate (14) enters the kidney area (6) through a fourth peristaltic pump (15) and is discharged through a fifth control valve (16);

s3.4, the control platform (20) can acquire related instructions from the cloud data center (19) to control cell culture, and meanwhile, cell culture data are uploaded to the cloud data center (19); the control platform (20) is also responsible for providing a patient life field (21) for the cells to be grown for future use; the culture temperature of the system is maintained by a constant temperature system (22), the system state is monitored by a sensor (23), and the system is connected with a control platform (20) through a data interface (24).

7. The method for producing EGF in mixed cell and mock cell culture artificial nest device according to claim 1, wherein the detecting step of step S4 is as follows: taking out the enzyme label plate, sequentially adding 200 mu L of standard substance, and incubating the sample in the micropore at 25 ℃ for 1 h; after washing the plate 3 times, 200. mu.L of substrate was added to each well; incubating in a backlight at 25 deg.C for 20 min; the reaction was stopped by adding 50. mu.L of stop solution to each well, and then measured using a full-automatic enzyme standard meter, and 3 replicates of each sample were averaged.

Technical Field

The invention belongs to the field of intelligent manufacturing of cytokine-based biological products, and particularly relates to a method for producing epidermal growth factors in a mixed cell and simulated cell culture artificial nest device.

Background

Cytokines are a class of biologically active small molecule proteins secreted by cells, which generally regulate cell growth, differentiation and effects by binding to corresponding receptors, act as molecular messengers, allowing immune system cells to communicate with each other to generate coordination of target antigens, have regulatory and effector functions in many diseases, and thus, cytokines and their receptors are useful for immunotherapy.

Because of the high efficiency of the cell factor, the cell factor is clinically applied to the treatment of various diseases such as tumor, metabolic diseases and the like, but the problems exist, most of the occurrence and development of the diseases are not determined by a single type cell and a single physicochemical factor, the influence of the cell factor on the diseases is more dependent on the network homeostasis and balance of the cell factor formed by various cell factors, most of the clinical application of the cell factor is not endogenous cell factors generated by patients, and the cell factor has many or unknown relations to the in vivo cell and molecular network of the patients when being applied, so that the clinical treatment effect of many cell factors is far inferior to the in vitro effect; secondly, single cytokine therapy is likely to cause severe cytokine toxicity in vivo, and the half-life of cytokines is short and biological activity is likely to be lost.

One of the important methods for producing the traditional epidermal factor is to construct transgenic cells to produce the epidermal growth factor by using a gene recombination technology under a 2D cell culture condition, wherein in the process of constructing the transgene, a gene transfection vector approximately comprises a virus vector and a non-virus vector, a retrovirus vector can continuously and effectively express a target gene, but the expression and the safety of virus proteins still have doubts; adenovirus vectors do not fuse with host genes, sometimes require repeated transduction, and may elicit immune and inflammatory responses; adeno-associated virus vectors are characterized by small harmfulness, wide application range, stable target gene products, and the like, but the improvement is still ongoing due to the problem of low utilization efficiency. The commonly used non-viral vectors comprise liposome, polymer and the like, the liposome is easy to cause immune recognition reaction to be degraded by a reticuloendothelial system due to complex macromolecules formed by the liposome and target cells, and the polymer vector has potential toxicity and efficiency problems. Secondly, in order to pursue the difference between in vivo synthesis and in vitro synthesis, the production of many protein molecules uses mammalian cells to produce protein molecules, but the culture process of mammalian cells usually depends on serum culture, but the traditional culture method is easy to cause mycoplasma and other virus contamination.

In vivo production of a certain protein factor is not the independent action of a single cell, but the result of the combined action of a plurality of cells and molecules under the condition of a plurality of physicochemical factors.

Disclosure of Invention

Aiming at the defects, the invention provides a method for producing the epidermal growth factor, which can achieve the same or similar effect with the synthesis of the epidermal growth factor in vivo by performing simulation control on physicochemical factors of the microenvironment of human histiocytes.

The principle and structure of the artificial nest device used in the invention refer to the patent: the simulation culture method of stem cells (patent application number: 201910315977.5) can simulate the processes of temperature, nutrition, acid-base balance, oxygen balance, carbon dioxide balance, metabolite discharge and the like in a human body in a cell culture system.

The invention solves the technical problem that the steps for producing the epidermal growth factor are as follows:

1. preparing a mixed cell culture solution and a cell nutrient solution;

2. setting parameters of the artificial nest device;

3. loading the mixed cell culture solution into a stem cell nest, and starting a circulating device to culture cells;

4. cytokine detection was performed from the collected cell supernatant using an ELISA kit.

Further, the mixed cell culture solution in step 1 is composed of 60-80% by volume of human fibroblasts, 1% by volume of mast cells, macrophages, dendritic cells, Langerhans cells and chromophagemids, 0.5% by volume of epidermal stem cells, 0.005% by volume of CD4+ T cells, 0.01% by volume of CD8+ T cells, wherein the cell density is 1 × 10⁷mL, the remainder was supplemented with cell nutrient solution.

Further, the cell nutrient solution in step 1 comprises the following components: 50ng/L of angiotensin, 98 mu g/L of aldosterol, 66pg/L of B-type brain natriuretic peptide, 2.26nmol/L of digoxin, 55 mu g/L of hyaluronic acid, 28 mu g/L of laminin, 56 mu g/L of IV-type collagen, 75 mu g/L of III-type procollagen peptide, 10.2nmol/L of folic acid, 396pmol/L of vitamin B12, 3mmol/L of glucose, 136mmol/L of sodium ion, 5mmol/L of potassium ion, 1mmol/L of magnesium ion, 2.2mmol/L of calcium ion, 10ng/L of salvia miltiorrhiza and 5ng/L of quercetin, wherein the salvia miltiorrhiza and the quercetin are selectively added.

Further, the parameters of the artificial nest device in the step 2 are as follows: the pressure is 90-220mmHg, the pH is 7.35-7.45, the temperature is 36.2-37.5 ℃, the oxygen content (including dissolved oxygen and bound oxygen) is 15-50 mL/100mL of culture solution, and the carbon dioxide content (including dissolved state and bound state) is 30-80 mL/100mL of culture solution.

Further, the artificial nest device in the step 3 is operated as follows:

(1) before the device operates, the spleen area is free of nutrient solution, a first control valve in the liver area is opened to enable the nutrient solution to be actively conveyed from the stomach area to the spleen area and reach the lowest set value of the liquid level of the spleen area, under the power driving of the heart area (a first peristaltic pump), the nutrient solution reaches the heart area (the first peristaltic pump) and enters the lung area, and the nutrient solution receives oxygen and carbon dioxide from the gas permeation membrane in the lung area and then enters a stem cell nest to provide nutrition and oxygen for stem cells wrapped in the simulated extracellular matrix; the gas exchange is powered by the cooperation of a second peristaltic pump and a second control valve, and the oxygen and the carbon dioxide are provided by sterile air;

(2) the nutrient solution flows out of the stem cell nest through a third control valve and enters the spleen area;

(3) part of nutrient solution in the spleen area and nutrient solution from the liver area enter a heart area (a first peristaltic pump) together, and then enter a stem cell nest after passing through the lung area to supply nutrition and oxygen for the stem cells; the other part of the urine enters the kidney area through the driving of a third peristaltic pump and returns to the spleen area through a fourth control valve; the kidney area is provided with a specific dialysis membrane which can filter metabolic wastes such as urea and the like generated in the growth process of the stem cells, so that the influence of the metabolic wastes on the growth of the stem cells is avoided; the dialysate enters the kidney area through a fourth peristaltic pump and is discharged through a fifth control valve;

(4) the control platform acquires related instructions from the cloud data center to control cell culture, and uploads cell culture data to the cloud data center; the control platform is also responsible for providing a patient life field for cell growth for future application of cell therapy; the culture temperature of the system is maintained by a constant temperature system, the system state is monitored by a sensor, and the system is connected with a control platform through a data interface.

Furthermore, the container and the related components of the pipeline used in the cell culture process are disposable, so that the cell safety is ensured; the related components of the container and the pipeline are made of polypropylene, polystyrene or polyethylene and the like which meet the medical and sanitary requirements, and are sterilized and provided in an aseptic packaging mode.

Has the advantages that:

the invention designs the cell combination of corresponding tissues during the synthesis of the human epidermal growth factor, simultaneously uses an artificial nest device which is automatic and can simulate the survival conditions of cells in the human body, designs a simulated nutrient solution for simulating the nutrition in the human body, and simultaneously establishes simulated conditions of temperature, nutrition, acid-base balance, oxygen balance, carbon dioxide balance and metabolite discharge in the human body during the production of the epidermal growth factor in the human body by utilizing the artificial nest, so that the synthesis of the epidermal growth factor is closer to the conditions in the human body than the conventional 2D cell culture conditions.

Drawings

Fig. 1 is a schematic view of an artificial nest device.

The kit comprises a main body, a stem cell nest, a heart area, a liver area, a lung area, a spleen area, a kidney area, a stomach area, a first control valve, a first peristaltic pump, a second control valve, a third peristaltic pump, a third control valve, a third peristaltic pump, a fourth control valve, a dialysate, a second peristaltic pump, a fourth peristaltic pump, a fifth control valve, a gas permeable membrane, a specific dialysis membrane, a cloud data center, a control platform, a life field, a constant temperature system, a sensor, a data interface, sterile air, fresh nutrient solution, a fresh nutrient solution and metabolic waste, wherein the stem cell nest, the heart area, the liver area, the lung area, the spleen area, the kidney area, the stomach area, the control valve, the first control valve, the dialysate, the second peristaltic pump, the.

Detailed Description

The present invention will be further described with reference to the following examples.